Zarbin, Marco A.
MacCumber, Mathew W.
Karcher, Helene
Adiguzel, Eser
Mayhook, Andrew
LaPrise, Andrew
Bilano, Ver L.
Igwe, Franklin
Ip, Michael S.
Wykoff, Charles C.
Funding for this research was provided by:
Novartis Pharma AG
Article History
Received: 17 January 2024
Accepted: 27 February 2024
First Online: 23 March 2024
Declarations
:
: Marco A. Zarbin: Consultant for Boehringer Ingelheim, EdiGene, Genentech, Inc./Roche, Illuminare, Life Biosciences, Novartis, Perfuse Therapeutics, Seeing Medicines, Smile Biotech, Tamarix Pharmaceuticals, and Tenpoint Therapeutics; holds stock in NVasc. Mathew W. MacCumber: Consultant for Alimera Sciences, Inc., Bausch + Lomb, Genentech, Inc./Roche, IVERIC bio, Novartis Pharma AG, Regeneron Pharmaceuticals, Inc.; research grants from Alimera Sciences, Inc., Apellis Pharmaceutical, Inc., REGENXBIO. Helene Karcher: employee and shareholder of Novartis. Eser Adiguzel: employee and shareholder of Novartis. Andrew Mayhook: contracted employee of Oxford PharmaGenesis. Andrew LaPrise: employee of Verana Health, Inc. Ver L. Bilano: employee of Novartis. Franklin Igwe: employee and shareholder of Novartis. Michael S. Ip: Consultant for Alimera, Allergan, Amgen, Apellis, Clearside Biomedical, Genentech, IVERIC bio, Novartis, Regeneron, and REGENXBIO; research support from 4DMT, Apellis, Biogen, Genentech, IVERIC bio, Lineage Cell Therapeutics, ONL Therapeutics, and REGENXBIO. Charles C. Wykoff: Consultant for 4DMT, AbbVie, Adverum Biotechnologies, Aerie, AGTC, Alcon, Alimera, Allergan, Allgenesis, Alnylam, Annexon Biosciences, Apellis, Arrowhead, Ascidian, Bausch + Lomb, Bayer, Bionic Vision Technologies, Boehringer Ingelheim, Cholgene, Clearside Biomedical, Curacle, Eyebiotech, EyePoint Pharmaceuticals, Foresite, Frontera Therapeutics, Genentech, Gyroscope Therapeutics, IACTA, IVERIC bio, Janssen, Kato Pharma, Kiora, Kodiak Sciences, Kriya Therapeutics, Merck, Nanoscope, Neurotech, NGM Biopharmaceuticals, Notal Vision, Novartis, OccuRx, Ocular Therapeutix, Ocuphire, OcuTerra, OliX, ONL, Opthea, Oxular, Palatin Technologies, Perceive Bio, Perfuse, PolyPhotonix, Ray, RecensMedical, Regeneron, REGENXBIO, Resonance, Roche, Sandoz, Sanofi, SciNeuro Pharmaceuticals, Stealth Biotherapeutics, Surrozen, Suzhou Raymon, Takeda, Thea, Therini, TissueGen, Valo, and Verana Health; research funding from 4DMT, Adverum Biotechnologies, AffaMed Therapeutics, Aldeyra, Alexion, Alimera, Alkahest, Allergan, Allgenesis, Amgen, Annexin Pharmaceuticals, Annexon Biosciences, Apellis, AsclepiX Therapeutics, Bayer, Boehringer Ingelheim, Chengdu Kanghong, Clearside Biomedical, Curacle, Eyebiotech, EyePoint Pharmaceuticals, Gemini, Genentech, GlaxoSmithKline, Graybug Vision, Gyroscope Therapeutics, IONIS, iRENIX, IVERIC bio, Janssen, Kodiak Sciences, LMRI, McMaster University, Nanoscope, Neurotech, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Ocuphire, OcuTerra, OliX, Ophthotech, Opthea, Oxurion, Oxular, Oyster Point Pharma, Perceive Bio, RecensMedical, Regeneron, REGENXBIO, Rezolute, Roche, Sam Chun Dang Pharm, Sandoz, Senju Pharmaceutical, Shanghai Henlius Biotech, Taiwan Liposome Company, Unity Biotechnology, Verily Life Sciences, and Xbrane Biopharma; on Advisory board of Aerie, Kato Pharma;. Board member of ASRS, Vit-Buckle Society; stock options for ONL, PolyPhotonix, RecensMedical, TissueGen, Visgenx, Vitranu.
: This study complied with the tenets of the Declaration of Helsinki. The analysis was based on de-identified patient data, and this study was reviewed and deemed exempt by the Western-Copernicus Group (WCG) Institutional Review Board (Puyallup, WA, USA) [CitationRef removed]. Informed consent was not required as the analysis was based on de-identified patient data.